Shots:

• The EMA Submission is based on P-l CHRYSALIS study to evaluate the safety and efficacy of Amivantamab as a monotherapy and in combination with Lazertinib in adult patients for the treatment of advanced NSCLC
• Result of CHRYSALIS Study assessed efficacy using overall response rate per Response Evaluation Criteria- CBR- DOR and PFS as well as the safety profile of amivantamab
• Amivantamab is an investigational- fully – human EGFR-MET bispecific antibody with immune cell – directing activity that targets tumours with activating and resistance EGFR mutations and MET mutations and amplifications

 ­ Ref: Janssen | Image: Janssen